More Stories

Informist, Thursday, Nov. 6, 2025

 

Please click here to read all liners published on this story

--Mankind Pharma Jul-Sept consol net profit INR 5.12 bln 
--Analysts saw Mankind Pharma Jul-Sept consol net profit INR 4.87 bln 
--Mankind Pharma Jul-Sept consol revenue INR 36.97 bln 
--Analysts saw Mankind Pharma Jul-Sept consol revenue INR 37.30 bln 
--Mankind Pharma Jul-Sept consol PAT INR 5.12 bln vs INR 6.53 bln year ago 
--Mankind Pharma Jul-Sept consol revenue INR 36.97 bln vs INR 30.61 bln 
--Mankind Pharma Apr-Sept consol PAT INR 9.50 bln vs INR 11.90 bln year ago 
--Mankind Pharma Apr-Sept consol revenue INR 72.68 bln vs INR 59.29 bln 
--Mankind Pharma Jul-Sept consol EBITDA INR 9.24 bln vs INR 8.50 bln yr ago 
--Mankind Pharma Jul-Sept consol EBITDA margin 25.0% vs 27.8% year ago 
--Mankind Pharma Jul-Sept consol gross margin 71.3% vs 71.5% year ago 
--Mankind Pharma Jul-Sept domestic ops revenue INR 31.84 bln vs INR 27.80 bln 
--Mankind Pharma Q2 revenue from exports INR 5.13 bln vs INR 2.81 bln 

 

By P. Madhu Kumar

 

MUMBAI – The consolidated revenue of Mankind Pharma Ltd. missed analysts' expectations and grew at the slowest pace in the last four quarters. Its profit growth fell for the fourth consecutive quarter and at the fastest clip year-on-year since the March quarter of 2022-23 (Apr-Mar), according to data available with Informist.

 

Mankind Pharma's consolidated net profit of INR 5.12 billion for Jul-Sept was nearly 22% lower on year but up nearly 17% sequentially. Its top line grew nearly 21% on year to INR 36.97 billion. Analysts had pegged the bottom line of the company at INR 4.87 billion and its revenue at INR 37.30 billion. 

 

The company's consolidated earnings before interest, tax, depreciation, and amortisation for the quarter stood at INR 9.24 billion, up nearly 9% on year and on quarter. The EBITDA margin of the company contracted 280 basis points on year but grew 120 bps on quarter to 25.0%.

 

Mankind Pharma's gross margin contracted by 20 basis points on year to 71.3% in the quarter under review. Revenue from its domestic business grew over 14% on year to INR 31.84 billion and revenue from exports jumped up nearly 83% to INR 5.13 billion. The company's domestic business was boosted by growth in its base business and Bharat Serum Vaccines consolidation.

 

"While chronic (therapy segment) continued an outperformance led by 1.3x and 1.2x in Cardiac and Antidiabetes respectively, OTC (over-the-counter segment) was impacted due to heavy rains along with GST 2.0 (cut in goods and services tax rates) and we expect growth recovery in H2 (Oct-Mar)...BSV (Bharat Serum Vaccines) growth initiatives progressing well - with double digit sequential growth led by mandate brands," Vice Chairman and Managing Director Rajeev Juneja said. 

 

On Thursday, shares of the company closed 2.6% lower at INR 2,309.10 on the National Stock Exchange.  End

 

Edited by Ashish Shirke

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.